Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
MabPharm (2181 HK)
Watchlist
14
Analysis
Health Care
•
China
Mabpharm Limitied manufactures medical products. The Company produces cancer treatment drugs, immune diseases drugs, biosimilar drugs, and other products. Mabpharm markets its products throughout China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
MabPharm
•
20 May 2019 15:09
Mabpharm IPO Preview: Mixed Prospects of Phase 3 Drug Candidates
MabPharm (2181 HK) is a pre-revenue biopharmaceutical company in China with a focus on drugs and biosimilars for cancers and autoimmune diseases....
Arun George
Follow
584 Views
Share
bearish
•
MabPharm
•
17 May 2019 15:58
MabPharm (迈博医药) IPO: Fairly Valued and Lacks Biotech Investors
MabPharm, a biotech company backed by CDH Investment, launched book building today. In our previous insights, we have discussed the company's...
Ke Yan, CFA, FRM
Follow
630 Views
Share
bearish
•
MabPharm
•
15 Apr 2019 11:34
MabPharm (迈博医药) IPO: Thoughts on Valuation (Part 2)
MabPharm is expected to launch its IPOsoon. In our previous insights (links provided below), we provided a detailed analysis of the company's core...
Ke Yan, CFA, FRM
Follow
849 Views
Share
bearish
•
MabPharm
•
21 Feb 2019 13:45
MabPharma (迈博医药) IPO: Assembled for a Trade?
MabPharma, backed by Chinese private equity investor CDH, is seeking to list in Hong Kong. In this insight, we will discuss the following...
Ke Yan, CFA, FRM
Follow
826 Views
Share
First
Previous
1
2
3
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x